Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma

NCT04937387 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04937387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04937387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
July 29, 2021
Completion date
August 5, 2024
Enrollment
359 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

asthma